Labiotech.eu

News and Trends 15 Nov 2022

Bel Group and Standing Ovation partner on cheese proteins

Dairy giant Bel Group and start-up Standing Ovation are partnering on incorporating casein milk protein into Bel’s alternative cheese offerings. In September, Bel acquired an equity stake in Standing Ovation. Standing Ovation has developed a precision fermentation process that produces caseins of non-animal origin. These proteins are identical to those present in milk. Standing Ovation’s […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Potential new lead compounds for treatment of depression and anxiety disorders

Currently, various classes of drugs are available for the treatment of mental illnesses – such as depression and anxiety disorders. However, although these drugs have benefits, they can also be associated with adverse side-effects. A research group has conducted a study to identify new drugs that could potentially be used for the treatment of neuropsychiatric […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

More News! 15 Nov 2022

Sequana Medical has positive results for heart failure therapy drug

Sequana Medical has had some very positive top-line results from a phase 2a study, that the company says reinforces its view that direct sodium removal (DSR) is a potential disease modifying heart failure therapy. The study called SAHARA was testing its first-generation DSR product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients with […]

November 15, 2022 - 3 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

Researchers awarded £2M to develop drugs to prevent epileptic seizures in children

Scientists at Aston University in the U.K. have started work on a project that will look for new drug treatments to prevent the onset of childhood epilepsy. The three-year Medical Research Council (MRC) funded project is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, partnered with Bristol […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Avanzanite Bioscience looks to commercialize innovative medicines for rare diseases in Europe

Avanzanite Bioscience B.V. has officially launched its commercial-stage enterprise, to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators. Avanzanite, a fully authorized distributor of medicinal products, partners with biopharmaceutical collaborators through flexible, bespoke licensing and distribution partnerships across Europe. The company’s business […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

First patient dosed in Nouscom colorectal cancer study

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a randomized phase 2 clinical trial evaluating NOUS-209 in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab versus pembrolizumab alone. NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of mismatch repair/microsatellite instable high […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Beckley Psytech completes treatment resistant depression and alcohol use disorder study

Beckley Psytech, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, has completed its phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), which is under development for treatment resistant depression and alcohol use disorder. The double-blind, randomized, single ascending dose study […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Biotheus enters agreement with Hansoh Pharma for bispecific antibody

Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, has entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus’ EGFR/MET bispecific antibody (also known as PM1080) in China, Hong Kong, Macao and Taiwan. Under the terms of the agreement, Hansoh will be granted by […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Fooditive takes world first bee-free honey a step closer

Large scale production trials of the first bee-free honey will start in the New Year thanks to Dutch-based ingredients company, Fooditive. The process of mass-producing a bio-identical honey means that the need to intensively farm honeybees will be eliminated and Fooditive aims to beat a scalable, provenanced supply. Not only will it provide the benefits […]

November 15, 2022 - 2 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS

3P BioPharmaceuticals and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat pathologies such as amyotrophic lateral sclerosis (ALS) or Parkinson’s disease. 3P BioPharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in the process development and cGMP manufacturing of biological products, and BrainEver is a French biotechnology company focusing on […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

More News! 14 Nov 2022

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

Minoryx Therapeutics and Neuraxpharm Group have announced a strategic alliance for the European rights to a new therapy for rare central nervous system (CNS) disease. The companies have entered into a license agreement for leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD). Under the agreement, Minoryx grants Neuraxpharm […]

November 14, 2022 - 3 minutesmins - By Liza Laws

More News! 14 Nov 2022

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

BioSenic’s systemic autoimmune disease platform, originally designed by Medsenic, is now developing controlled dosages and new formulations adapted to a significant number of important indications with unmet medical needs. BioSenic specializes in serious autoimmune and inflammatory diseases as well as cell repair. The update follows the announcement of the merger between Bone Therapeutics and Medsenic […]

November 14, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Bel Group and Standing Ovation partner on cheese proteins

Potential new lead compounds for treatment of depression and anxiety disorders

Sequana Medical has positive results for heart failure therapy drug

Researchers awarded £2M to develop drugs to prevent epileptic seizures in children

Avanzanite Bioscience looks to commercialize innovative medicines for rare diseases in Europe

First patient dosed in Nouscom colorectal cancer study

Beckley Psytech completes treatment resistant depression and alcohol use disorder study

Biotheus enters agreement with Hansoh Pharma for bispecific antibody

Fooditive takes world first bee-free honey a step closer

BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!